List of Therapeutic Companies in Ohio - 36

Created in 2011 as a spin-out of Cincinnati Children's Hospital Medical Center (CCHMC), Airway Therapeutics has extensive expertise in protein development for applications in the lungs and pediatrics. Airway Therapeutics is in advanced preclinical phase of developing AT-100 (rhSP-D), a product targeting bronchopulmonary dysplasia (BPD) in newborns.

Akrotome Imaging, Inc. is focused on the clinical translation of cancer-targeted molecular probes into enhanced approaches for surgery and diagnostics, leading to improved outcomes and patient quality of life while positively impacting healthcare economics. Akrotome is a Delaware C Corporation with offices in Ohio, Indiana, and California. The company was first incorporated in 2008 and the current management team has been in place since May of 2012. The company's approach stresses the efficient use of capital, coupled with strategies that emphasize the fastest routes to the clinical market with the lowest regulatory overhead.

Allinaire is developing humanized anti-endothelial monocyte activating polypeptide II (EMAP II) monoclonal antibodies, which are currently being progressed as a potential disease-modifying treatment for PAH. Allinaire was founded in 2016 by BioMotiv (www.biomotiv.com; now managed by Advent Life Sciences, www.adventls.com), with the licensed technology from Indiana University. EMAP II is a non-classical cytokine which impacts apoptosis, cell injury, endothelial cell function and inflammation. Based on the pioneering work by the scientific founders, Matthias Clauss, PhD and Irina Petrache, MD, and their colleagues at Indiana University and National Jewish Health, Allinaire Therapeutics and their network of preclinical and clinical scientists, have demonstrated a pivotal pathogenic role of EMAP II in cardiopulmonary diseases, including pulmonary arterial hypertension (PAH), chronic obstructive pulmonary disease (COPD), and viral-induced acute lung injury.

Armatus Bio is a biotechnology company that specializes in precision gene therapy for raising expectations in FSHD.

Athersys is a clinical stage biopharmaceutical company with a growing pipeline of highly differentiated, potential best in class therapeutics to treat significant and life-threatening diseases. We are engaged in the discovery and development of innovative new medicines designed to extend and enhance the quality of human life. Through the application of our proprietary technologies, we have established a pipeline of therapeutic product development programs in multiple disease areas. This pipeline includes both stem cell therapy and pharmaceuticals.

Atreon Orthopedics is a tissue regeneration company powered by breakthrough regenerative technology and renowned scientific expertise. Tendon and ligament injuries affect ten million people yearly, spanning all lifestyles and demographics. Atreon is committed to dramatically improving healing and long-term outcomes for patients encountering these soft-tissue injuries. ROTIUM®, our initial product for rotator cuff repair, is a bioresorbable wick designed as a scaffold to harness and hold biologically active substances at the repair site providing a pro-healing environment that promotes healthy tissue and native tissue regeneration. Recently published human and animal studies and over 10,000 cases have shown a safe and effective solution to improving biology, restoring function, and improving rotator cuff success rates.

AtriCure, Inc. provides innovative technologies for the treatment of Afib and related conditions. Afib affects more than 37 million people worldwide. Electrophysiologists, cardiothoracic and thoracic surgeons around the globe use AtriCure technologies for the treatment of Afib, reduction of Afib related complications and post-operative pain management. AtriCure's Isolator® Synergy™ Ablation System is the first medical device to receive FDA approval for the treatment of persistent Afib. AtriCure's AtriClip® Left Atrial Appendage Exclusion System products are the most widely sold LAA management devices worldwide. AtriCure's Hybrid AF™ Therapy is a minimally invasive procedure that provides a lasting solution for long-standing persistent Afib patients. AtriCure's cryoICE cryoSPHERE®+ and cryoSPHERE MAX™ probes are cleared for temporary ablation of peripheral nerves to block pain, providing pain relief in cardiac and thoracic procedures. For more information, visit AtriCure.com or follow us on X (formerly Twitter) @AtriCure.

Auxilium Health is developing low-cost and smart biomaterials for hard-to-heal wounds. Our mission is to empower patients to take control of their healing journey by providing technology that actively heals and monitors wound infections, enabling faster recovery times and better quality of life for patients. We are providing a smarter way to heal wounds, one patient at a time.

Basking is developing the first in class agent (BB-031) targeting von Willebrand Factor (VWF) along with a direct acting reversal agent (BB-025) to immediately the pharmacological effect of BB-031 in the event of bleeding. BB-031 is an RNA aptamer optimized for rapid onset of action and short duration of effect. Basking will initiate a Phase 2 trial in acute ischemic stroke in late 2023 and is exploring further application in pulmonary embolism in preclinical studies. The technology is based on two decades of translational research on RNA aptamers as therapeutic agents for cardiovascular diseases.

Celloram Inc. is a preclinical stage company founded in 2018. Our team of experienced leaders and scientists share a passion for improving the health and well-being of patients and families affected by cancer and chronic disease. Celloram has a deep sense of social responsibility. We are dedicated to the community in which we reside and work, and where we honor our commitment to promote diversity by inspiring, educating and developing the next generation of scientists and leaders. Celloram now leverages its key discoveries to develop unique forms of cell therapy and small molecule therapeutics that harness our body’s own unique potential to heal and battle chronic illnesses including cancer, autoimmune disease, chronic inflammatory and metabolic disorders. Our mission and vision stem from our strong belief in the potential of new, less toxic therapies with the power to ignite our body’s self-healing process. With an ideal location at University Circle, Cleveland, OH, Celloram has benefited greatly from partnerships with health care leaders at two of the nation’s leading academic medical centers, including Case Western Reserve University School of Medicine and University Hospitals Cleveland Medical Center. Supported by a highly motivated and dedicated group of partners and investors, Celloram has developed a pipeline of four unique therapeutics: Sopprimerex, Protexi, NOVS-100, and CLM-022. These cutting-edge therapies are in distinct phases of preclinical development and are rapidly advancing through essential steps that will position each core asset for entry into clinical trials and evaluation by the FDA. Our team at Celloram is committed to sharing our discoveries and advancing them for the benefit of human health.

Cincinnati Children's, a nonprofit academic medical center established in 1883, offers services from well-child care to treatment for the most rare and complex conditions. It is the Department of Pediatrics at the University of Cincinnati College of Medicine and trains more than 600 residents and clinical fellows each year. Cincinnati Children's is a force in pediatric research and offers some of the best research-based education and training programs in the nation. We are proud to be an Equal Opportunity Employer that values and treasures Diversity, Equity, and Inclusion. We are committed to creating an environment of dignity and respect for all our employees, patients, and families (EEO/AA).

CinRx Pharma is a biotech company advancing a diverse portfolio of high-impact medicines through clinical development with a unique hub-and-spoke business model. CinRx’s approach combines financing with the efficient progression of therapeutic candidates within its portfolio, each managed by CinRx’s central infrastructure and operating team. Current CinCos address areas of high unmet medical need including metabolic, gastrointestinal, and oncology. Differentiated by an asset selection process agnostic to therapeutic area, a strategic CRO partnership, and insights from thousands of development programs, CinRx identifies, funds and accelerates promising drugs with the potential to have the highest impact on patients’ quality of life. CinRx Pharma is headquartered in Cincinnati, Ohio.

Clarametyx Biosciences Inc. is a clinical stage biotechnology company developing immune-enabling biologic therapies to fight life-threatening infections. Our novel technology platform targets the protective barrier around bacteria, known as biofilms.

Cleveland Diagnostics is developing a breakthrough technology to discover a new class of diagnostics tests with high sensitivity and specificity for many cancers – early on, when cancer is still curable.

CollaMedix develops medical devices that are based on collagen. These devices are made using electrocompaction technology. Electrocompacted collagen devices can enhance soft tissue repair and augmentation. One example is CollaFabric®, a load-bearing fabric made from collagen.

Patented, Drug-Free, Faster, and More Effective Treatment for Vaginal Infections. Powered by Project Medtech.

Deep Lens is a digital healthcare company focused on enabling faster recruitment of the best-suited cancer patients for clinical trials at the time of diagnosis using VIPER. Deep Lens' AI-driven cloud platform gives care teams, trial coordinators and oncologists visibility into all available trials and the ability to collaborate on groundbreaking cancer research across all cancer types.

Diasome Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company pioneering hepatocyte cell targeting to restore hepatocyte metabolism and treat metabolic diseases. Restoring hepatocyte function addresses the root dysregulations in common metabolic diseases like diabetes, obesity, and dyslipidemia. Our therapies leverage the Hepatocyte's natural regulatory functions, aiming to deliver superior patient outcomes and improved disease management.

Eikonoklastes Therapeutics is an early stage biopharmaceutical company focused on rapidly advancing innovative medicines for numerous areas of significant unmet clinical need, starting with neurodegenerative diseases. We are iconoclasts who are passionate about finding new and better ways to treat disease. Our first-in-class gene therapy moves beyond single defective gene replacement. It is a transformational, disease-modifying gene supplement therapy with a unique mechanism of action that provides extra copies of a critical gene to cause overexpression of a critical neurotrophic factor that is essential for neuromuscular signaling and function. Our initial focus is on Amyotrophic Lateral Sclerosis (ALS, Lou Gehrig’s Disease), a rare, yet debilitating nerve disease that causes progressive muscle degeneration and eventual death. An estimated 5,000 new patients in the U.S. are diagnosed each year with ALS, and there are few treatment options beyond supportive care. Our dynamic discovery and development approach allows us to focus on accelerated approvals and outsized returns for ALS and potentially other neurodegenerative diseases such as Parkinson’s, Huntington’s, Alzheimer’s, traumatic brain injury, and more.

Forge is a gene therapy development engine, focused on enabling access to life changing gene therapies and helping bring them from idea into reality. We partner with innovators in the gene therapy community: scientists, physicians, biotech/pharma companies, and patient groups. We bring expertise in gene therapy manufacturing and therapeutics development to the table, helping champion teams that are navigating the long road from the lab bench to the bedside. With a patients-first approach, we are forging new models for working together to better accelerate these transformative medicines to reach those who need them most.

Genosera is revolutionizing the gene therapy field with its next generation gene therapy treatments that can help stop the progression of diseases and allow patients to regain their health. Founded in 2019, Genosera is a privately held, gene therapy biotechnology company located in Columbus, Ohio.

Haima Therapeutics is a pre-clinical stage biotechnology company focused on developing bio-inspired therapies for the treatment of bleeding and other blood-related ailments. We have developed a novel, nanoparticle-based synthetic hemostatic technology, called SynthoPlate, that can staunch hemorrhagic bleeding by binding to the site of injury and amplifying your body’s natural clotting mechanisms. Haima Therapeutics and Case Western Reserve University entered into an option to license agreement in April of 2018. Haima Therapeutics is located at the BioEnterprise incubator centrally located in the University Circle area near Case Western Reserve University, University Hospitals, and the Cleveland Clinic.

MiCo Biomed USA is a biotechnology company that offers Optimiser™ Plus Microfluidic Plates for Life Science and Diagnostic Immunoassays.

Navidea Biopharmaceuticals, Inc. (NYSE: NAVB) is a leader in precision medicine with immuno-targeted products designed to help identify the sites and pathways of undetected disease and enable better diagnostic accuracy, clinical decision-making, targeted treatment and, ultimately, patient care. Applying our Manocept™ technology, Navidea seeks to develop next-generation targeted diagnostics and therapies for cancer, autoimmune conditions, and other inflammatory diseases, with an initial focus on personalized Rheumatoid Arthritis diagnostics. The company, founded in 1983, maintains headquarters in Dublin, Ohio.

NeuroTherapia, Inc. is a clinical-stage company developing oral, small molecule therapeutics that inhibit microglia cells, which are known to express proteins that drive inflammation. The company was founded in 2015 by the Cleveland Clinic and two of its physician scientists.

NovAccess Global is a biomedical company accelerating and investing in novel cancer diagnostics and therapeutics.

NovelMed Therapeutics is a privately held biotechnology company that has developed cutting-edge highly selective therapeutics for complement-mediated diseases.

Noxsano is a wound care company dedicated to developing medical dressings that deliver bio-signaling molecules to enable effective treatment of acute and chronic wounds. Noxsano's patent pending technology has been shown in pre-clinical testing to restore normal wound healing to ischemic (chronic) wounds and accelerate the healing of acute and burn wounds

Onconetix (formerly Blue Water Biotech Inc.) (Nasdaq: BWV) is a biopharmaceutical company focused on developing transformational therapies to address significant health challenges globally. The company holds the rights to proprietary technology developed at the University of Oxford, Cincinnati Children's Hospital Medical Center (CCHMC), and St. Jude Children's Hospital. The company is developing a universal flu vaccine that will provide protection from all virulent strains in addition to licensing a novel norovirus (NoV) S&P nanoparticle versatile virus-like particle (VLP) vaccine platform from CCHMC to develop vaccines for multiple infectious diseases, including norovirus/rotavirus and malaria, among others. Additionally, Blue Water Vaccines is developing a Streptococcus pneumoniae (pneumococcus) vaccine candidate, designed to specifically prevent the highly infectious middle ear infections, known as Acute Otitis Media (AOM), in children.

Optimvia is a biopharmaceutical company specializing in engineering enzymes and their cofactors to synthesize complex therapeutic molecules. The company leverages its ADEPT™ platform to engineer biosynthetic heparin and aims to manufacture non-animal derived heparin as proof of principle for its platform.

Solving GPCR structures

ProtoKinetix (PKTX) is a research and development company leading the way in cell survival solutions. Its patented anti-aging glycopeptide (AAGP) is a revolutionary discovery with incredible opportunity to shape the future of ophthalmology, dermatology, transplant support and biomanufacturing. Based on a molecule found in nature and harnessed by a world-class research team, this anti-aging glycopeptide helps more cells survive longer and has the capability to change health care forever. With AAGP, health therapies will become more effective, more affordable and more accessible. We will get closer to cures for conditions such as Type 1 diabetes, macular degeneration, heart disease and stroke. More lives will improve, and more people will get the treatments they deserve. ProtoKinetix has harnessed a molecule found in nature with the power to transform lives and the future of health care. Founded in 2002, ProtoKinetix secured a patent for anti-aging glycopeptide (AAGP), a naturally-occurring molecule that regenerates cells for animals surviving in arctic temperatures. AAGP has gone through a series of tests in laboratories throughout Europe and North America conducted by some of the best researchers in the world. Backed by a decade of promising clinical research, all trials to date have shown that AAGP is safe, stable and effective in protecting and regenerating cells. This molecule could be the link to improved treatments for transplants, Type 1 diabetes, macular degeneration, stroke, heart disease and so much more. There is endless potential, and we’ve only seen the tip of the iceberg. Become part of the next great medical discovery.

Sermonix Pharmaceuticals, founded by David Portman, MD—a leading clinical researcher and expert in women’s health—focuses on developing targeted therapeutics to treat ESR1-mutated metastatic breast and gynecological cancers.

Synapse Biomedical Inc (SBI) was founded in September 2002 to commercialize the NeuRx Diaphragm Pacing System (DPS)® that has been developed over a twenty-year period at Case Western Reserve University and the University Hospitals of Cleveland. The innovative research performed at these institutions has led to significant advances in the state of the art of electrical stimulation for the treatment of chronic respiratory insufficiency. This innovation allows the technology to meet clinical needs, beyond the ability of the currently available systems, in Spinal Cord Injuries, in the diaphragm conditioning in muscular dystrophies (such as ALS) and in respiratory short-term intensive care settings.

Trailhead Biosystems merges developmental biology and cell therapeutics with cutting edge hardware, and computerized experimental design and analysis to perform process-specific parameter optimization for customers seeking to develop cell therapies. Implementing Quality by Design (QbD) principles, cell culture optimization is done by utilizing Design of Experiment (DoE) theory combined with Multivariate Data Analysis (MVDA). This allows Trailhead to generate mathematical models of the biological system, understand the effector-response relationship in cell culture, and provide a systems biology analysis of the differentiation space. DoE-based experimental design and robotic execution greatly reduce the number of experiments and time needed for optimizing a large number of variables simultaneously. You will see that Trailhead Biosystems is novel from its ability to: Have computer-based experimental designs executed for advanced cell culture Gain knowledge into how cell culture affects gene expression in cells Mathematically model the effector/response space so virtual experiments can be performed and enable exploration of cell biology to predict how additives will create desirable cell culture fates Address optimization challenges for cell purity and potency Understand the variance in cell manufacturing methods

We are a US biotech company focused on restoring cell health and resilience, with profound initial indications for the treatment of cancers and rare diseases, the protection of multiple organ injuries, and the effective reversal of aging. We are looking for investors, development partners, or licensees. Interested parties please contact us for further information and discussions.